Grifols (GRFS) Cash from Investing Activities (2010 - 2020)
Grifols (GRFS) posted Cash from Investing Activities of -$125.1 million for Q1 2020, up 71.26% quarter-over-quarter from -$435.2 million in Q4 2019, and up 56.61% year-on-year from -$79.9 million in Q2 2019.
Grifols (GRFS) Cash from Investing Activities (2010 - 2020) Analysis & Trends
Grifols (GRFS) has reported Cash from Investing Activities for 10 consecutive years, with -$125.1 million the latest figure, recorded in Q1 2020.
- Cash from Investing Activities for Q1 2020 came in at -$125.1 million, up 56.61% year-over-year; the trailing twelve-month figure through Mar 2020 was -$94.3 million (down 223.87% YoY), and the FY2025 annual result was -$674.0 million, down 171.19% from the prior year.
- Cash from Investing Activities was -$125.1 million for Q1 2020 at Grifols, up from -$435.2 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $2.4 billion in Q4 2017 and troughed at -$798.7 million in Q3 2016.
- Average Cash from Investing Activities over 5 years is $281.0 million, with a median of -$120.2 million recorded in 2016.
- Year-over-year, Cash from Investing Activities tumbled 1045.5% in 2016 and surged 2116.99% in 2017.
- Over 5 years, Cash from Investing Activities stood at -$120.2 million in 2016, then soared by 2116.99% to $2.4 billion in 2017, then tumbled by 68.9% to $754.2 million in 2018, then sank by 157.7% to -$435.2 million in 2019, then jumped by 71.26% to -$125.1 million in 2020.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$125.1 million in Q1 2020, -$435.2 million in Q4 2019, and -$288.3 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -3.92 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -1.04 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -574.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.79 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -10.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -716.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.77 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 785.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -125.09 Mn |
| Mar 31, 2020 | -125.09 Mn |
| Dec 31, 2019 | -435.16 Mn |
| Dec 31, 2019 | -435.16 Mn |
| Mar 31, 2019 | -288.25 Mn |
| Mar 31, 2019 | -288.25 Mn |
| Dec 31, 2018 | 754.17 Mn |
| Dec 31, 2018 | 754.17 Mn |
| Jun 30, 2018 | -509.49 Mn |
| Jun 30, 2018 | -509.49 Mn |
| Mar 31, 2018 | 119.73 Mn |
| Mar 31, 2018 | 119.73 Mn |
| Dec 31, 2017 | 2.43 Bn |
| Dec 31, 2017 | 2.43 Bn |
| Jun 30, 2017 | 88.45 Mn |
| Jun 30, 2017 | 88.45 Mn |
| Mar 31, 2017 | 1.98 Bn |
| Mar 31, 2017 | 1.98 Bn |
| Dec 31, 2016 | -120.24 Mn |
| Dec 31, 2016 | -120.24 Mn |